Aclarion, Inc. Files Amendment No. 1 to Form S-1
Ticker: ACONW · Form: S-1/A · Filed: Jan 31, 2024 · CIK: 1635077
| Field | Detail |
|---|---|
| Company | Aclarion, INC. (ACONW) |
| Form Type | S-1/A |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.00001, $7.1 million, $2.14, $0.0345, $1.00 |
| Sentiment | neutral |
Complexity: moderate
Sentiment: neutral
Topics: S-1/A, Aclarion, SEC Filing, Registration Statement, Amendment
TL;DR
<b>Aclarion, Inc. has filed an amendment to its S-1 registration statement, providing updated corporate and financial information.</b>
AI Summary
Aclarion, Inc. (ACONW) filed a Amended IPO Registration (S-1/A) with the SEC on January 31, 2024. Aclarion, Inc. filed an amendment to its S-1 registration statement on January 31, 2024. The company was formerly known as Nocimed, Inc., with a name change on February 26, 2015. Aclarion, Inc. is incorporated in Delaware and has its fiscal year end on December 31. The company's business and mailing address is 8181 Arista Place, Suite 100, Broomfield, CO 80021. The filing is related to the 1933 Securities Act, with SEC file number 333-276648.
Why It Matters
For investors and stakeholders tracking Aclarion, Inc., this filing contains several important signals. This amendment indicates ongoing efforts by Aclarion, Inc. to comply with SEC regulations for public offerings or reporting. The filing provides crucial details for potential investors and stakeholders regarding the company's structure, history, and regulatory compliance.
Risk Assessment
Risk Level: low — Aclarion, Inc. shows low risk based on this filing. The risk is low as this is a routine amendment to a registration statement, not indicating immediate financial distress or significant new risks.
Analyst Insight
Monitor future filings for details on the company's public offering status and financial performance.
Key Numbers
- 2024-01-31 — Filing Date (Amendment No. 1 to Form S-1)
- 0001683168-24-000585 — Accession Number (Unique identifier for the filing)
- 2015-02-26 — Name Change Date (Date Nocimed, Inc. became Aclarion, Inc.)
Key Players & Entities
- Aclarion, Inc. (company) — Filer and subject of the filing
- Nocimed, Inc. (company) — Former name of Aclarion, Inc.
- 2024-01-31 (date) — Filing date of the amendment
- 8181 Arista Place, Suite 100, Broomfield, CO 80021 (address) — Business and mailing address
- 1933 Act (regulation) — SEC Act under which the filing is made
- 333-276648 (filing_number) — SEC file number
Forward-Looking Statements
- Aclarion, Inc. will complete its initial public offering (IPO) within the next 6-12 months. (Aclarion, Inc.) — medium confidence, target: 2025-01-31
FAQ
When did Aclarion, Inc. file this S-1/A?
Aclarion, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on January 31, 2024.
What is a S-1/A filing?
A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Aclarion, Inc. (ACONW).
Where can I read the original S-1/A filing from Aclarion, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Aclarion, Inc..
What are the key takeaways from Aclarion, Inc.'s S-1/A?
Aclarion, Inc. filed this S-1/A on January 31, 2024. Key takeaways: Aclarion, Inc. filed an amendment to its S-1 registration statement on January 31, 2024.. The company was formerly known as Nocimed, Inc., with a name change on February 26, 2015.. Aclarion, Inc. is incorporated in Delaware and has its fiscal year end on December 31..
Is Aclarion, Inc. a risky investment based on this filing?
Based on this S-1/A, Aclarion, Inc. presents a relatively low-risk profile. The risk is low as this is a routine amendment to a registration statement, not indicating immediate financial distress or significant new risks.
What should investors do after reading Aclarion, Inc.'s S-1/A?
Monitor future filings for details on the company's public offering status and financial performance. The overall sentiment from this filing is neutral.
How does Aclarion, Inc. compare to its industry peers?
Aclarion, Inc. operates in the medical laboratories sector, as indicated by its SIC code 8071.
Are there regulatory concerns for Aclarion, Inc.?
The filing is made under the Securities Act of 1933, which governs the initial offering and registration of securities.
Industry Context
Aclarion, Inc. operates in the medical laboratories sector, as indicated by its SIC code 8071.
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the initial offering and registration of securities.
What Investors Should Do
- Review the full S-1/A filing for detailed financial statements and business descriptions.
- Track future SEC filings from Aclarion, Inc. for updates on their public offering or reporting status.
- Research the company's business operations and market position within the medical laboratory industry.
Key Dates
- 2024-01-31: Filing of Amendment No. 1 to Form S-1 — Provides updated information for the company's registration statement.
- 2015-02-26: Company Name Change — Date Nocimed, Inc. officially changed its name to Aclarion, Inc.
Year-Over-Year Comparison
This is an amendment to a previously filed S-1, indicating updates rather than a completely new filing.
Filing Stats: 4,606 words · 18 min read · ~15 pages · Grade level 15.2 · Accepted 2024-01-31 17:26:34
Key Financial Figures
- $0.00001 — 0 shares of our common stock, par value $0.00001 per share. The shares of common stock
- $7.1 million — wever, we may receive proceeds of up to $7.1 million from the sale of our common stock to th
- $2.14 — orted on the Nasdaq Capital Market, was $2.14 per share. Our warrants offered in conn
- $0.0345 — Capital Market on January 24, 2024 was $0.0345 per IPO Warrant. We have received defi
- $1.00 — nimum bid price requirement of at least $1.00 per share and (ii) the requirement to h
- $2,500,000 — d (ii) the requirement to have at least $2,500,000 in stockholders' equity (the "Stockhold
- $134.5B — ts. Aclarion's technology addresses the $134.5B U.S. low back and neck pain market, whi
- $150 million — logies selected to participate in their $150 million Back Pain Consortium (BACPAC) Research
Filing Documents
- aclarion_s1a1.htm (S-1/A) — 2807KB
- aclarion_ex2301.htm (EX-23.1) — 2KB
- aclarion_ex2302.htm (EX-23.2) — 2KB
- 0001683168-24-000585.txt ( ) — 7381KB
- acon-20230930.xsd (EX-101.SCH) — 41KB
- acon-20230930_cal.xml (EX-101.CAL) — 49KB
- acon-20230930_def.xml (EX-101.DEF) — 161KB
- acon-20230930_lab.xml (EX-101.LAB) — 314KB
- acon-20230930_pre.xml (EX-101.PRE) — 274KB
- aclarion_s1a1_htm.xml (XML) — 775KB
Risk Factors
Risk Factors 18 Information Regarding Forward-Looking Statements 62 The White Lion Transaction 63
Use of Proceeds
Use of Proceeds 64 Dividend Policy 65 Market Price of and Dividends on Common Equity and Related Stockholder Matters 65
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 66
Business
Business 76 Management, Governance, Director Compensation, Executive Compensation 104 Certain Relationships and Related Party Transactions 115 Principal Stockholders 116
Description of Capital Stock
Description of Capital Stock 117 Selling Securityholder 122 Plan of Distribution 123 Legal Matters 125 Experts 125 Where You Can Find More Information 125 Index to Financial Statements F-1 ii ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated by reference herein or any amendment thereto. You should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference herein is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or have been incorporated by reference as exhibits to the registration heading " Where You Can Find More Information ." You should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provide